" class="no-js "lang="en-US"> Meddy El Alaoui - Medtech Alert
Wednesday, September 17, 2025

Breaking News

Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Astellas and Cullgen Enter into Strategic Collaboration and Option Agreement to Advance Innovative Targeted Protein Degraders Auxilius Pharma Raises Seed Funding of $1 Million and Commences its Clinical Program Captivate Bio and EverCell Bio partner on Human Cell Modeling Services for Cell and Gene Therapy Markets Applied StemCell Partners with CIRM to Provide Clinical-Grade iPSCs and Access to Its Proprietary Gene Editing Technologies Alentis Therapeutics Receives IND Clearance from FDA for ALE.C04 for the Treatment of CLDN1+ Tumors
Meddy El Alaoui

Meddy El Alaoui

About Meddy El Alaoui

PhD in biochemistry

Working at Covalab, a biotech company specialized in antibody synthesis and production. I’m involved in research project on antibody based therapies against breast cancer in order to improve treatment efficacy with many collaborations. I previously worked on the development of high throughput screening assays using structural triglycerides and phospholipids.

Related Story

COVID-19

 Covalab Invests More Than €1 Million in Bioproduction Operations for Antibodies for Covid-19 Diagnostics | Pharmtech Focus

Covalab Invests More Than €1 Million in Bioproduction Operations for Antibodies for Covid-19 Diagnostics

May 23 2022

Covalab, a biotechnology company that specializes in the development and production of recombinant proteins and […]

Industry News

 Oncodesign

Oncodesign, Covalab, CheMatech and ABX-CRO Launch DRIVE™-MRT, a Premium Complete, Integrated Service Offer for Radiopharmaceuticals Drug Discovery and Generation

July 2 2021

ONCODESIGN (ALONC -FR0011766229), a French biopharmaceutical company dedicated to precision medicine, Covalab (Bron, France), a biotechnology company specializing […]